Virtual Library
Start Your Search
Ariadna Roqué
Author of
-
+
EP1.12 - Small Cell Lung Cancer/NET (ID 202)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Small Cell Lung Cancer/NET
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.12-15 - Oncologic Treatments and Outcomes for Small-Cell Lung Cancer Patients with Brain Metastases (Now Available) (ID 1877)
08:00 - 18:00 | Author(s): Ariadna Roqué
- Abstract
Background
Brain metastases (BM) are common in patients with small-cell lung cancer (SCLC), and are associated with short survival. Few data are available on this specific population of patients with SCLC and BM, as they are usually excluded from prospective randomized clinical trials.
Method
We present data on all patients diagnosed with BM from SCLC from the Cancer Register of the Hospital Universitari Dr. Josep Trueta during 2013–2017. Age, gender, and treatment in patients were recorded. Data cut-off for survival analysis was 28th March 2019.
Result
We identified 50 patients with SCLC and BM. Median age: 66 y (range: 48–82 y); male: 39 (78%). Synchronous BM were observed at the diagnosis of primary lung cancer in 33 (66%) patients. Impact of treatments on median overall survival (mOS) is summarized in Table 1. Only 1 patient received brain surgery (with an OS of 6.5 months). One-third of patients (34%) received best supportive treatment as unique treatment. The 1-year OS was 18% in our study.
Table 1 Treatment % mOS
(without treatment)mOS
(with treatment)p-value Brain radiotherapy 52 % 1.4 m 9.1 m < 0.000001 Chemotherapy 50 % 1.5 m 6.9 m =0.003 Brain radiotherapy and chemotherapy 34 % 1.6 m 10.7 m =0.000331
Conclusion
Our real-world data reinforce the need for better therapies to improve the prognosis of patients with SCLC and BM.
